Julie Renee Brahmer is an American thoracic oncologist. She is the co-director of the Upper Aerodigestive Department within the Bloomberg~Kimmel Institute for Cancer Immunotherapy at Johns Hopkins University and the Marilyn Meyerhoff Professor in Thoracic Oncology.
Julie Brahmer | |
|---|---|
| Born | Nebraska, USA |
| Spouse |
Michael G. Nast
(m. 2004; died 2004) |
| Academic background | |
| Education | BSc, Chemistry and Philosophy, 1989, Creighton University MD, 1993, University of Nebraska Medical Center |
| Academic work | |
| Institutions | Johns Hopkins University |
Early life and education
editBrahmer was born and raised in Nebraska to a farmer father and nurse mother.[1] She graduated cum laude from Creighton University in 1989[2] with a Bachelor of Science degree in Chemistry and Philosophy.[3] Brahmer then earned her medical degree in 1993 at the University of Nebraska Medical Center.[4] Following her medical degree, Brahmer completed her internship and residency in Internal Medicine at the University of Utah. After being appointed Chief Medical Resident, she completed her fellowship in Medical Oncology at the Kimmel Cancer Center at Johns Hopkins University.[3]
Career
editUpon completing her fellowship, Brahmer joined the faculty at Johns Hopkins (JHU) in 2001.[5] During her early tenure at JHU, Brahmer participated as a researcher on a trial for an immune checkpoint inhibitor drug called MDX-1106 (nivolumab).[6] In 2010, she oversaw the first in-human, open-label, phase I, dose-escalation study of MDX-1106 in refractory solid tumors.[7] As a result of her research into the treatment and prevention of lung cancer and mesothelioma, Brahmer was appointed a member of the American Society of Clinical Oncology and the Eastern Cooperative Oncology Group Thoracic Committee and Cancer Prevention Steering Committee. She was also elected to the Scientific Advisory Board for the LUNGevity Foundation.[8] Brahmer also became a founding board member of the National Lung Cancer Partnership and sat on the Lung Cancer Research Foundation's Medical Advisory Board.[5]
In January 2015, Brahmer was appointed director of the Thoracic Oncology Program at the Johns Hopkins Kimmel Cancer Center.[5] The following month, she was recognised as the March LUNGevity Hero for her work in the field of immunotherapy for lung cancer patients.[9] Brahmer also expanded on her original research on nivolumab and found that people with squamous-non-small cell lung cancer who received nivolumab lived, on average, 3.2 months longer than those receiving chemotherapy.[10]
In 2015, Brahmer collaborated with oncologist Russell Hales and thoracic surgeon Richard Battafarano to launch a multidisciplinary lung cancer program within the Kimmel Cancer Center.[11] As such, she was appointed director of the newly created program at the Kimmel Cancer Center in January 2015.[5] In this new role, Brahmer expanded on her research into targeted immunotherapy to focus on how it can benefit those with lung cancer mutations with lower levels of the PD-L1 protein.[12] Brahmer was also promoted to professor of oncology at the Johns Hopkins School of Medicine while serving in this new role.[13]
On June 1, 2022, Brahmer was named the inaugural recipient of the Marilyn Meyerhoff Professorship in Oncology within the Sidney Kimmel Cancer Center at Johns Hopkins.[14] She was also recognized by Clarivate Analytics as being among the top cited researchers in her field.[15]
Personal life
editBrahmer married Michael G. Nast in June 2004. He died later in December while scuba diving in Mexico.[16]
References
edit- ^ Piana, Ronald (December 25, 2019). "Lung Cancer Expert Julie R. Brahmer, MD, MSc, Was an Early Believer in Immunotherapy—and Still Is". ASCO Post. Retrieved November 16, 2022.
- ^ "Creighton University holds commencement". Sioux City Journal. June 6, 1989. Retrieved November 16, 2022 – via newspapers.com.
- ^ a b "Julie Renee Brahmer, M.D." Johns Hopkins University. Retrieved November 16, 2022.
- ^ "UN Medical confers 558 Diplomas". Sioux City Journal. May 15, 1989. Retrieved November 16, 2022 – via newspapers.com.
- ^ a b c d "Julie Brahmer Appointed Thoracic Cancer Director at Johns Hopkins". Johns Hopkins University. January 12, 2015. Retrieved November 16, 2022.
- ^ Brahmer, J. R.; Topalian, S.; Wollner, I. (May 20, 2008). "Safety and activity of MDX-1106 (ONO-4538), an anti-PD-1 monoclonal antibody, in patients with selected refractory or relapsed malignancies". Journal of Clinical Oncology. 26 (15): 3006. doi:10.1200/jco.2008.26.15_suppl.3006. Retrieved November 21, 2022.
- ^ Brahmer, Julie R.; Drake, Charles G.; Wollner, Ira (July 1, 2010). "Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates". Journal of Clinical Oncology. 28 (19): 3167–3175. doi:10.1200/JCO.2009.26.7609. PMC 4834717. PMID 20516446.
- ^ "LUNGevity Foundation Announces Additions to Scientific Advisory Board". PR Newswire. February 5, 2014. Retrieved November 21, 2022.
- ^ "Dr. Julie Brahmer, MD, Named March LUNGevity Hero for Research in Groundbreaking Field of Immunotherapy". LUNGevity. February 2015. Retrieved November 21, 2022.
- ^ "Immunotherapy Drug Improves Survival for Common Form of Lung Cancer". Johns Hopkins University. May 31, 2015. Retrieved November 21, 2022.
- ^ "Joining Forces to Thwart Lung Cancer". Johns Hopkins University. March 3, 2016. Retrieved November 21, 2022.
- ^ McQuay, Jessica (May 8, 2017). "A New Weapon Against Lung Cancer". Johns Hopkins University. Retrieved November 21, 2022.
- ^ "Faculty appointments and promotions: September 2017". Johns Hopkins University. October 20, 2017. Retrieved November 21, 2022.
- ^ "Faculty appointments and promotions: March 2022". Johns Hopkins University. May 27, 2022. Retrieved November 21, 2022.
- ^ "56 Johns Hopkins scholars among world's most highly cited researchers". Johns Hopkins University. November 15, 2022. Retrieved November 21, 2022.
- ^ "Michael G. Nast". Intelligencer Journal. December 13, 2004. Retrieved November 16, 2022 – via newspapers.com.